NAYA Biosciences Inc (NAYA) Short-Term Debt to Equity

NAYA Biosciences (NAYA) is developing an oncotherapeutic system based on unique FLEX-NK antibodies, establishing a protected patent barrier. This price chart reflects the 1.05 metric. The startup is currently consolidating assets following a merger, focusing on preclinical validations and the search for partners. Additionally, NAYA Biosciences (NAYA) is building biomaterial delivery chains, ensuring safety and precision during medical testing.

This indicator measures the ratio of short-term liabilities to equity, determining the company's dependence on rapid loan repayment and the risk of asset impairment. Analyzing the historical trend of short-term loans to equity for NAYA Biosciences (NAYA), it is evident that the high cost of oncology R&D is offset by the attraction of venture capital and patent protection, ensuring the issuer's financial stability.